Research Status of Clinical Trials of Drugs and Interventions for Anxiety Disorders

doi:10.12114/j.issn.1007-9572.2021.00.069

Abstract

Abstract: As one of the most common mental diseases，there is no ideal clinical treatment for anxiety disorder.This paper summarized and analyzed the listed drugs for the treatment of anxiety disorders as well as the chemical drugs，traditional Chinese medicines and non-pharmaceutical interventions that are still in clinical trials at home and abroad，and commented on their mechanisms，advantages and disadvantages，so as to provide reference for the research and development of new drugs and clinical treatment measures for anxiety disorders.

Key words: Anxiety disorders, Psychotropic drugs, Clinical trial, Review

摘要： 焦虑症是常见的精神疾病，目前临床并无理想处置措施。本文总结分析了目前治疗焦虑症的已上市药物以及国内外尚处于临床试验阶段的化学药、中药和非药物干预手段，并对其机制和优缺点进行了评述，为焦虑症的新药物研发和临床处置措施研究提供借鉴。

关键词: 焦虑症, 精神治疗药物, 临床试验, 综述

LI Maijia,YE Tianyuan,QI Dongmei, et al. Research Status of Clinical Trials of Drugs and Interventions for Anxiety Disorders　[J]. Chinese General Practice, 2021, 24(11): 1418-1425. DOI: 10.12114/j.issn.1007-9572.2021.00.069.
李麦嘉,叶田园,齐冬梅等. 焦虑症治疗药物和干预手段临床试验研究现状[J]. 中国全科医学, 2021, 24(11): 1418-1425. DOI: 10.12114/j.issn.1007-9572.2021.00.069.

References

［1］RODRIGUES P A，ZANINOTTO A L，NEVILLE I S，et al．Transcranial magnetic stimulation for the treatment of anxiety disorder［J］．Neuropsychiatr Dis Treat，2019，15：2743-2761．DOI：10.2147/ndt.s201407.
［2］WHO.Depression and Other Common Mental Disorders：Global Health Estimates（2017）［J］．2017，Licence：CC BY-NC-SA 3.0 IGO.
［3］KIM S Y，JEON S W，LIM W J，et al.The relationship between serum vitamin D levels，C-reactive protein，and anxiety symptoms［J］．Psychiatry Investigation，2020，17（4）：312-319．DOI：10.30773/pi.2019.0290.
［4］HUANG Y Q，WANG Y，WANG H，et al.Prevalence of mental disorders in China：a cross-sectional epidemiological study［J］．Lancet Psychiatry，2019，6（3）：211-224．DOI：10.1016/s2215-0366（18）30511-x.
［5］BANDELOW B.Current and novel psychopharmacological drugs for anxiety disorders［J］．Adv Exp Med Biol，2020，1191：347-365．DOI：10.1007/978-981-32-9705-0_19.
［6］SCHIELE M A，DOMSCHKE K.Epigenetics at the crossroads between genes，environment and resilience in anxiety disorders［J］．Genes Brain Behav，2018，17（3）：e12423．DOI：10.1111/gbb.12423.
［7］陈兆斌，张博，刘秀敏，等.焦虑症发病机制的研究进展［J］．天津中医药，2018，35（4）：316-320．DOI：10.11656/j.issn.1672-1519.2018.04.21.
CHEN Z B，ZHANG B，LIU X M，et al.Research progress on the pathogenesis of anxiety［J］．Tianjin Journal of Traditional Chin Medicine，2018，35（4）：316-320．DOI：10.11656/j.issn.1672-1519.2018.04.21.
［8］SIGEL E，STEINMANN M E.Structure，function，and modulation of GABA（A） receptors［J］．J Biol Chem，2012，287（48）：40224-40231．DOI：10.1074/jbc.R112.386664.
［9］SARTORI S B，SINGEWALD N.Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders［J］．Pharmacol Ther，2019，204：107402．DOI：10.1016/j.pharmthera.2019.107402.
［10］BALON R，STARCEVIC V.Role of benzodiazepines in anxiety disorders［J］．Adv Exp Med Biol，2020，1191：367-388．DOI：10.1007/978-981-32-9705-0_20.
［11］KUMAR M，DILLON G H.Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA（A） receptors［J］．Eur J Pharmacol，2016，775：149-158．DOI：10.1016/j.ejphar.2016.02.031.
［12］GONZALEZ L A，GATCH M B，TAYLOR C M，et al.Carisoprodol-mediated modulation of GABAA receptors：in vitro and in vivo studies［J］．J Pharmacol Exp Ther，2009，329（2）：827-837．DOI：10.1124/jpet.109.151142.
［13］OLIVIER B.Serotonin：a never-ending story［J］．Eur J Pharmacol，2015，753：2-18．DOI：10.1016/j.ejphar.2014.10.031.
［14］BELIVEAU V，GANZ M，FENG L，et al.A high-resolution in vivo atlas of the human brain's serotonin system［J］．J Neurosci，2017，37（1）：120-128．DOI：10.1523/JNEUROSCI.2830-16.2016.
［15］RAVINDRAN L N，STEIN M B.The pharmacologic treatment of anxiety disorders：a review of progress［J］．J Clin Psychiatry，2010，71（7）：839-854．DOI：10.4088/JCP.10r06218blu.
［16］LISTED N.Drugs for anxiety disorders ［J］．Med Lett Drugs Ther，2019，61（1578）：121-126.
［17］UNGVARI Z，TARANTINI S，YABLUCHANSKIY A，et al.Potential adverse cardiovascular effects of treatment with fluoxetine and other selective serotonin reuptake inhibitors （SSRIs） in patients with geriatric depression：implications for atherogenesis and cerebromicrovascular dysregulation［J］．Frontiers in Genetics，2019，10：898．DOI：10.3389/fgene.2019.00898.
［18］STRAWN J R，GERACIOTI L，RAJDEV N，et al.Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients：an evidence-based treatment review［J］．Expert Opin Pharmacother，2018，19（10）：1057-1070．DOI：10.1080/14656566.2018.1491966.
［19］MOKHBER N，AZARPAZHOOH M R，KHAJEHDALUEE M，et al.Randomized，single-blind，trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder［J］．Psychiatry Clin Neurosci，2010，64（2）：128-133．DOI：10.1111/j.1440-1819.2009.02055.x.
［20］SCHANZER B，RIVAS-GRAJALES A M，KHAN A，et al.Novel investigational therapeutics for generalized anxiety disorder （GAD）［J］．Expert Opin Investig Drugs，2019，28（11）：1003-1012．DOI：10.1080/13543784.2019.1680638.
［21］BERGMAN J，ROOF R A，FURMAN C A，et al.Modification of cocaine self-administration by buspirone （buspar?）：potential involvement of D3 and D4 dopamine receptors［J］．Int J Neuropsychopharmacol，2013，16（2）：445-458．DOI：10.1017/S1461145712000661.
［22］TAO M，HAN Y J，GAO J F，et al.Efficacy and safety of tandospirone in the treatment of patients with anxiety disorder［J］．Zhonghua Yi Xue Za Zhi，2012，92（13）：920-923.
［23］NISHITSUJI K，TO H，MURAKAMI Y，et al.Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression：results of a comparatively high dosage trial［J］．Clin Drug Investig，2004，24（2）：121-126．DOI：10.2165/00044011-200424020-00007.
［24］SHIMODA K，SHIBASAKI M，INABA T，et al.Carbonyl reduction of timiperone in human liver cytosol［J］．Pharmacol Toxicol，1998，83（4）：164-168．DOI：10.1111/j.1600-0773.1998.tb01463.x.
［25］KREYS T J，PHAN S V.A literature review of quetiapine for generalized anxiety disorder［J］．Pharmacotherapy，2015，35（2）：175-188．DOI：10.1002/phar.1529.
［26］SLEE A，NAZARETH I，BONDARONEK P，et al.Pharmacological treatments for generalised anxiety disorder：a systematic review and network meta-analysis［J］．Lancet，2019，393（10173）：768-777．DOI：10.1016/S0140-6736（18）31793-8.
［27］PANULA P，NUUTINEN S.The histaminergic network in the brain：basic organization and role in disease［J］．Nat Rev Neurosci，2013，14（7）：472-487．DOI：10.1038/nrn3526.
［28］OBARA I，TELEZHKIN V，ALRASHDI I，et al.Histamine，histamine receptors，and neuropathic pain relief［J］．Br J Pharmacol，2020，177（3）：580-599．DOI：10.1111/bph.14696.
［29］MICó J A，PRIETO R.Elucidating the mechanism of action of pregabalin：α（2）δ as a therapeutic target in anxiety［J］．CNS Drugs，2012，26（8）：637-648．DOI：10.2165/11634510-000000000-00000.
［30］JOYCE J N，MILLAN M J.Dopamine D3 receptor antagonists as therapeutic agents［J］．Drug Discov Today，2005，10（13）：917-925．DOI：10.1016/S1359-6446（05）03491-4.
［31］KLEIN M O，BATTAGELLO D S，CARDOSO A R，et al．Dopamine：functions，signaling，and association with neurological diseases［J］．Cell Mol Neurobiol，2019，39（1）：31-59．DOI：10.1007/s10571-018-0632-3.
［32］CHEN Q Y，WU L J，WU Y Q，et al.Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines［J］．Mol Med Rep，2009，2（5）：811-817．DOI：10.3892/mmr_00000177.
［33］RAGHAV D，MAHANTY S，RATHINASAMY K.Characterizing the interactions of the antipsychotic drug trifluoperazine with bovine serum albumin：probing the drug-protein and drug-drug interactions using multi-spectroscopic approaches［J］．Spectrochim Acta A Mol Biomol Spectrosc，2020，226：117584．DOI：10.1016/j.saa.2019.117584.
［34］TARDY M，DOLD M，ENGEL R R，et al.Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia［J］．Cochrane Database Syst Rev，2014（7）：CD009396．DOI：10.1002/14651858.CD009396.pub2.
［35］YANG L K，TAO Y X.Physiology and pathophysiology of the β3-adrenergic receptor［J］．Prog Mol Biol Transl Sci，2019，161：91-112．DOI：10.1016/bs.pmbts.2018.09.003.
［36］GIOVANNITTI J A Jr，THOMS S M，CRAWFORD J J.Alpha-2 adrenergic receptor agonists：a review of current clinical applications［J］．Anesth Prog，2015，62（1）：31-39．DOI：10.2344/0003-3006-62.1.31.
［37］BRODDE O E，MICHEL M C.Adrenergic and muscarinic receptors in the human heart［J］．Pharmacol Rev，1999，51（4）：651-690.
［38］SUMIYOSHI T，SUZUKI K，SAKAMOTO H，et al．Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy［J］．Neuropsychopharmacology，1995，12（1）：57-64．DOI：10.1038/sj.npp.1380239.
［39］SETOGUCHI M，SAKAMORI M，TAKEHARA S，et al.Effects of iminodibenzyl antipsychotic drugs on cerebral dopamine and alpha-adrenergic receptors［J］．Eur J Pharmacol，1985，112（3）：313-322．DOI：10.1016/0014-2999（85）90776-9.
［40］ZAMPONI G W，STRIESSNIG J，KOSCHAK A，et al.The physiology，pathology，and pharmacology of voltage-gated calcium channels and their future therapeutic potential［J］．Pharmacol Rev，2015，67（4）：821-870．DOI：10.1124/pr.114.009654.
［41］BEKIRCAN-KURT C E，DERLE ?IFT?I E，KURNE A T，et al.Voltage gated calcium channel antibody-related neurological diseases［J］．World Journal of Clinical Cases，2015，3（3）：293-300．DOI：10.12998/wjcc.v3.i3.293.
［42］BALDWIN D S，AJEL K，MASDRAKIS V G，et al.Pregabalin for the treatment of generalized anxiety disorder：an update［J］．Neuropsychiatric Disease and Treatment，2013，9：883-892．DOI：10.2147/NDT.S36453.
［43］LI Z，TAYLOR C P，WEBER M，et al.Pregabalin is a potent and selective ligand for α（2）δ-1 and α（2）δ-2 calcium channel subunits［J］．Eur J Pharmacol，2011，667（1/2/3）：80-90．DOI：10.1016/j.ejphar.2011.05.054.
［44］MOUSAILIDIS G，PAPANNA B，SALMON A，et al.Pregabalin induced visual hallucinations - a rare adverse reaction［J］．BMC Pharmacol Toxicol，2020，21（1）：16．DOI：10.1186/s40360-020-0395-6.
［45］BANDELOW B，MICHAELIS S，WEDEKIND D.Treatment of anxiety disorders［J］．Dialogues Clin Neurosci，2017，19（2）：93-107.
［46］STEIN D J，CAMERON A，AMREIN R，et al.Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder［J］．Int Clin Psychopharmacol，2002，17（4）：161-170．DOI：10.1097/00004850-200207000-00002.
［47］TILLER J W，BOUWER C，BEHNKE K.Moclobemide for anxiety disorders：a focus on moclobemide for panic disorder［J］．Int Clin Psychopharmacol，1997，12（Suppl 6）：S27-30.
［48］黄科，贺梅红，张玉霞，等.九味镇心颗粒治疗广泛性焦虑症疗效与安全性系统评价［J］．山东中医杂志，2018，37（6）：462-468.
HUANG K，HE M H，ZHANG Y X，et al.Systematic review of efficacy and safety of Jiuwei Zhenxin granules in treatment of generalized anxiety disorder［J］．Shandong Journal of Traditional Chinese Medicine，2018，37（6）：462-468.
［49］姚旭东，刘芳.帕罗西汀联合参芪五味子颗粒治疗广泛性焦虑症的效果［J］．中国当代医药，2018，25（5）：15-17．DOI：10.3969/j.issn.1674-4721.2018.05.005.
YAO X D，LIU F.Effect of Paroxetine combined with Shenqiwuweizi Granule in the treatment of generalized anxiety disorder［J］．China Modern Medicine，2018，25（5）：15-17．DOI：10.3969/j.issn.1674-4721.2018.05.005.
［50］任凌.稳心颗粒对心血管疾病患者伴焦虑的临床疗效观察［J］．实用心脑肺血管病杂志，2012，20（1）：148．DOI：10.3969/j.issn.1008-5971.2012.01.094.
REN L.Clinical effect of Wenxin Granule on anxiety in patients with cardiovascular disease［J］．Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease，2012，20（1）：148．DOI：10.3969/j.issn.1008-5971.2012.01.094.
［51］李东芳，陈英杰，张绪欣，等.养血清脑颗粒治疗缺血性脑血管病后焦虑抑郁的临床观察［J］．中西医结合心脑血管病杂志，2011，9（12）：1449-1450.
LI D F，CHEN Y J，ZHANG X X，et al.Clinical observation on Yangxue qingnao granules for treatment of ischemic cerebrovascular disease comorbid depression and anxiety disorders［J］．Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease，2011，9（12）：1449-1450.
［52］向琴.柏子养心丸联合草酸艾司西酞普兰片治疗广泛性焦虑症56例［J］．中医杂志，2013，54（13）：1148-1149.
［53］张东子，陈亚兰，刘建丛.百乐眠胶囊联合艾司西酞普兰片治疗失眠伴抑郁焦虑的临床效果［J］．中国医药导报，2019，16（17）：133-136.
ZHANG D Z，CHEN Y L，LIU J C.Clinical effect of Bailemian Capsules combined with Escitalopram Tablets in the treatment of insomnia with depression and anxiety ［J］．China Medical Herald，2019，16（17）：133-6.
［54］周建民.七叶神安分散片治疗广泛性焦虑症疗效观察［J］．中草药，2009，40（10）：I0007-I0009.
［55］刘小河，杨忠奇，冼绍祥，等.温胆片对焦虑模型大鼠行为学和单胺类神经递质的影响［J］．广州中医药大学学报，2012，29（6）：674-8．DOI：10.13359/j.cnki.gzxbtcm.2012.06.020.
LIU X H，YANG Z Q，XIAN S X，et al.Effect of Wendan Tablets on Behaviors and Monoamine Neurotransmitters in Rat Model of Anxiety ［J］．Journal of Guangzhou University of Traditional Chinese Medicine，2012，29（6）：674-8．DOI：10.13359/j.cnki.gzxbtcm.2012.06.020.
［56］王文秀，陈洁，荣立洋，等.温胆片治疗广泛性焦虑症（痰热内扰证）的临床疗效观察［J］．广州中医药大学学报，2019，36（11）：1679-1683．DOI：10.13359/j.cnki.gzxbtcm.2019.11.001.
WANG W X，CHEN J，RONG L Y，et al.Clinical Observation of Wendan Tablets in Treatment of Generalized Anxiety Disorder with Phlegm-heat Disturbance Syndrome ［J］．Journal of Guangzhou University of Traditional Chinese Medicine，2019，36（11）：1679-1683．DOI：10.13359/j.cnki.gzxbtcm.2019.11.001.
［57］谷丛欣，肖庆国，范彦蓉，等.温胆片联合黛力新治疗广泛性焦虑症［J］．长春中医药大学学报，2014，30（3）：470-2．DOI：10.13463/j.cnki.cczyy.2014.03.036.
GU C X，XIAO Q G，FAN Y R，et al.Clinical research of Wendanpian combined with Dailixin for the treatment of generalized anxiety ［J］．Journal of Changchun University of Chinese Medicine，2014，30（3）：470-472．DOI：10.13463/j.cnki.cczyy.2014.03.036.
［58］CRASKE M G，STEIN M B，ELEY T C，et al.Anxiety disorders［J］．Nat Rev Dis Primers，2017，3：17024．DOI：10.1038/nrdp.2017.24.
［59］HIGA-MCMILLAN C K，FRANCIS S E，RITH-NAJARIAN L，et al.Evidence base update：50 years of research on treatment for child and adolescent anxiety［J］．J Clin Child Adolesc Psychol，2016，45（2）：91-113．DOI：10.1080/15374416.2015.1046177.
［60］LOERINC A G，MEURET A E，TWOHIG M P，et al.Response rates for CBT for anxiety disorders：Need for standardized criteria［J］．Clin Psychol Rev，2015，42：72-82．DOI：10.1016/j.cpr.2015.08.004.
［61］CIRILLO P，GOLD A K，NARDI A E，et al.Transcranial magnetic stimulation in anxiety and trauma-related disorders：a systematic review and meta-analysis［J］．Brain Behav，2019，9（6）：e01284．DOI：10.1002/brb3.1284.
［62］CUI H R，JIANG L J，WEI Y Y，et al.Efficacy and safety of repetitive transcranial magnetic stimulation for generalised anxiety disorder：a meta-analysis［J］．General Psychiatry，2019，32（5）：e100051．DOI：10.1136/gpsych-2019-100051.
［63］LI M X，XING X，YAO L，et al.Acupuncture for treatment of anxiety，an overview of systematic reviews［J］．Complement Ther Med，2019，43：247-252．DOI：10.1016/j.ctim.2019.02.013.
［64］STUBBS B，VANCAMPFORT D，ROSENBAUM S，et al.An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders：a meta-analysis［J］．Psychiatry Res，2017，249：102-108．DOI：10.1016/j.psychres.2016.12.020.
［65］SAEED S A，CUNNINGHAM K，BLOCH R M.Depression and anxiety disorders：benefits of exercise，Yoga，and meditation［J］．Am Fam Physician，2019，99（10）：620-627.

[1]	FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063.
[2]	LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949.
[3]	CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807.
[4]	CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592.
[5]	ZHANG Mingyue, HOU Yan. Research Progress of Exhaled Nitric Oxide and Alveolar Nitric Oxide in Interstitial Lung Diseases [J]. Chinese General Practice, 2026, 29(18): 2571-2576.
[6]	MA Xiaoyu, MA Xiaomei, WU Guozhi, ZHENG Ya, GUO Qinghong. Research Progress of Neutrophil Extracellular Traps in Gastric Cancer [J]. Chinese General Practice, 2026, 29(17): 2425-2432.
[7]	LI Jiawei, GE Aoqi, GAO Xinyi, LI Juanjuan, YUAN Beibei. The Concept, Connotation, and Pathways of the Integration of Medical Care and Preventive Services in China: a Systematic Review [J]. Chinese General Practice, 2026, 29(16): 2156-2166.
[8]	WANG Yang, JIN Hua, YANG Sen, YANG Hui, YU Dehua. Reconfiguring the Functional Features of Primary Care in a Non-gatekeeping Context: a 15-Year Mixed-methods Systematic Review from China [J]. Chinese General Practice, 2026, 29(16): 2140-2155.
[9]	LIU Jialing, BAN Chengjun. An Exploration of Decentralized Clinical Trials in the Real World [J]. Chinese General Practice, 2026, 29(14): 1946-1952.
[10]	ZOU Jian, LI Wanping, GE Handa, JIN Zhe, RUFEINA· Tuerxun, LI Juan, WEI Anhua, FENG Da. Study on Potentially Inappropriate Medication Use among the Community Elderly Patients in Hubei Province [J]. Chinese General Practice, 2026, 29(13): 1759-1765.
[11]	ZHANG Qiang, ZHAO Wenxia, WANG Ziyi, YAN Le, LIANG Haowei, WANG Jinfan, FANG Jinhua, LU Cuncun. Interpretation of the Reporting Guideline for Systematic Reviews of Outcome Measurement Instruments (PRISMA-COSMIN for OMIs 2024) [J]. Chinese General Practice, 2026, 29(13): 1766-1775.
[12]	YE Xinying, YIN Ankang, LIU Dingling, LYU Xiang, WANG Yi. The Development of General Practice Department in General Hospitals under the DIP Payment Model [J]. Chinese General Practice, 2026, 29(11): 1378-1384.
[13]	SHI Yufeng, LU Chenxia, LYU Anqi, LI Xiaodong. Research Progress on the Relationship between Veillonella and Liver Diseases Based on the Theory of Intestinal-hepatic Axis [J]. Chinese General Practice, 2026, 29(11): 1488-1496.
[14]	SUN Yuchen, SHI Yaxin, SHI Wei. Advancements in the Treatment of Endometrial Hypofunction Diseases Using Menstrual Blood-derived Endometrium Stem Cells Combined with Traditional Chinese Medicine for Tonifying Kidney and Activating Blood in Regenerative Medicine [J]. Chinese General Practice, 2026, 29(11): 1481-1487.
[15]	WANG Gaoming, WANG Minghang, YANG Jiang, MENG Yuanyuan, ZHAO Di, DONG Xiaosheng. Systematic Evaluation and Reflection on the Quality of Bronchial Asthma Guidelines in China [J]. Chinese General Practice, 2026, 29(10): 1239-1245.